Abstract
Targeted radiation therapy (TRT) is undergoing another renaissance attributable to U.S. Food and Drug Administration approvals of 223RaCl2 (Xofigo; Bayer) and 177Lu-DOTATATE (Lutathera; Advanced Accelerator Applications) in 2013 and 2018, respectively. The former, though not a TRT agent, exploits
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
